farmakokinetiikka

name

• farmakokinetiikka

Works about farmakokinetiikka

• Automatable microplate-based in vitro assays for screening intestinal drug transport and metabolism
• Biofarmasia ja farmakokinetiikka
• Biopolymer-based nanoparticles for drug delivery
• Cellular and computational methods in corneal drug permeability, active transport and cytotoxicity studies
• Cellular, placental and in vivo pharmacokinetics of liposomal doxorubicin
• Central nervous system permeation of non-steroidal anti-inflammatory drugs and paracetamol in children
• Effect of cytochrome P450 2D6 and 3A enzyme inhibition on the metabolism of oxycodone
• Effects of cytochrome P450 enzyme inhibitors and inducers on the metabolism of S-ketamine
• Effects of cytochrome P450 enzyme inhibitors on the metabolism of drugs used in anaesthesiology
• Effects of cytochrome P450 enzyme inhibitors on the pharmacokinetics of nonsteroidal anti-inflammatory drugs and venlafaxine
• Effects of drug interactions and liver disease on the pharmacokinetics of ropivacaine
• Effects of gender, and SLCO1B1 and CYP7A1 polymorphisms on plasma bile acids in humans and the pharmacokinetics of therapeutic ursodeoxycholic acid
• Eläinlääkinnän farmakokinetiikka ja farmasia
• Farmakokinetiikan perusteet
• Improvement of the Caco-2 permeability model by genetic and hydrodynamic modifications
• In search of models for hepatic and placental pharmacokinetics
• In vitro cell models in predicting blood-brain barrier permeability of drugs
• Insights into retinal drug delivery
• Interplay of passive and active drug disposition in in vitro models of drug absorption and distribution
• Lääketieteellinen farmakologia ja toksikologia
• Lääkkeiden yhteisvaikutukset
• Mechanism-based inhibition of CYP2C8 by gemfibrozil in humans : characterisation of time and dose relationships
• Mesoporous silicon micro- and nanoparticles : a versatile tool for peptide delivery
• Modifications and carriers for improved oligonucleotide delivery : synthesis, analysis and biological testing
• Modulation by drug interactions and glial activation
• Neutron activation-based gamma scintigraphic imaging and scintigraphy-based pharmacokinetic modelling of per oral controlled release drug delivery
• Novel materials for controlled peptide delivery : mesoporous silicon and photocrosslinked poly(ester anhydride)s
• Novel prodrug structures for improved drug delivery
• Observations on the pharmacokinetics and pharmacodynamics of dexmedetomidine : clinical studies on healthy volunteers and intensive care patients
• Pharmacogenetics of carboxylesterase 1
• Pharmacokinetic interactions and pharmacogenetics of aliskiren
• Pharmacokinetic interactions of pioglitazone
• Pharmacokinetics of levosimendan and its metabolites in humans with special emphasis on the effect of renal and liver impairment
• Pharmacokinetics of montelukast and zafirlukast as affected by CYP inhibitors
• Pharmacokinetics of oxycodone and paracetamol in the elderly : a clinical pharmacokinetic study on orthopaedic surgical patients and healthy volunteers
• Pharmacokinetics, efficacy, and safety of pravastatin in children : studies in children with heterozygous familial hypercholesterolemia and in pediatric cardiac transplant recipients
• Polymer and lipid based nanocarriers for drug and gene delivery
• Population pharmacokinetics in support of analgesics and anaesthetics studies in special populations
• Retinal pigment epithelium as a barrier in drug permeation and as a target of non-viral gene delivery
• Studies on canine lower respiratory tract with special reference to inhaled corticosteroids
• Syöpälääkkeet
• The potential of prolyl oligopeptidase as a drug target
• The role of cytochrome P450 3A inducers and inhibitors in the metabolism and the effects of oxycodone
• The role of drug metabolism in drug discovery and development :
• Vanhusten lääkehoito